Amgen's third-quarter 2024 earnings call highlighted several positive trends and strong performance metrics that are likely to have a favorable short-term impact on the stock price. Here are the key points:

1. **Revenue and Earnings Growth**: Total revenues increased by 23% to $8.5 billion, and GAAP EPS increased by 62% due to strong sales performance and mark-to-market gains on equity investments[1][3].
2. **Product Sales**: Multiple products achieved double-digit sales growth, including Repatha, EVENITY, BLINCYTO, and TEZSPIRE. This indicates a robust product portfolio[1][2][3].
3. **International Growth**: International sales grew by 14%, reflecting successful strategies to expand global presence[1].
4. **Pipeline Advancements**: Positive Phase 3 results and marketing authorizations for several key products, including evolocumab and blinatumomab, suggest future growth potential[1][2].
5. **Financial Discipline**: Amgen reduced principal debt outstanding by $2.5 billion in the quarter and generated significant free cash flow, indicating sound financial management[1][3].
6. **Guidance Update**: The company raised its 2024 revenue and EPS guidance, reflecting confidence in its underlying business trends[1].

Given these strong results, positive guidance, and advancements in the pipeline, the stock is likely to experience a short-term positive impact.

**Rating: 2**